NOD 1
Alternative Names: NOD-1Latest Information Update: 11 Mar 2024
At a glance
- Originator Nodus Oncology
- Developer Nodus Oncology; The Lead Discovery Center
- Class Antineoplastics
- Mechanism of Action DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 17 Jan 2024 Early research in Cancer in the United Kingdom (unspecified route) (Nodus Oncology pipeline, January 2023)